Daiichi Ranbaxy Buy Gives Japanese Pharma Other Indian Firms
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's acquisition of a majority share of India's Ranbaxy Laboratories also would give the Japanese drug maker a chance to get a controlling interest in another Indian pharma, Zenotech. Ranbaxy owns 48 percent of Zenotech, and Daiichi would have to make a separate offer for majority shares of that company. Ranbaxy interests in other Indian pharmas are included in the larger acquisition deal, including 14.9 percent interests each in Jupiter Bioscience, Kribs Biochemical and Orchid Pharma. (Click here for more